0001209191-14-002558.txt : 20140109 0001209191-14-002558.hdr.sgml : 20140109 20140109142600 ACCESSION NUMBER: 0001209191-14-002558 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140106 FILED AS OF DATE: 20140109 DATE AS OF CHANGE: 20140109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EnteroMedics Inc CENTRAL INDEX KEY: 0001371217 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2800 Patton Rd CITY: St Paul STATE: MN ZIP: 55113 MAIL ADDRESS: STREET 1: 2800 Patton Rd CITY: St Paul STATE: MN ZIP: 55113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EVNIN LUKE CENTRAL INDEX KEY: 0001134657 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33818 FILM NUMBER: 14518426 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 54TH STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-01-06 0 0001371217 EnteroMedics Inc ETRM 0001134657 EVNIN LUKE C/O MPM ASSET MANAGEMENT 200 CLARENDON ST., 54TH FLOOR BOSTON MA 02116 1 0 0 0 Common Stock 2014-01-06 4 S 0 81720 2.50 D 1588033 I See footnote Common Stock 2014-01-07 4 S 0 190334 2.50 D 1397699 I See footnote Common Stock 2014-01-08 4 S 0 284531 2.50 D 1113168 I See footnote The shares were sold as follows: 68,003 by MPM BioVentures III-QP, L.P. ("BV III QP"), 4,572 by MPM BioVentures III, L.P. ("BV III"), 2,054 by MPM BioVentures III Parallel Fund, L.P. ("BV III PF"), 5,747 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV III KG") and 1,344 by MPM Asset Management Investors 2002 BVIII LLC ("AM LLC"). The shares are held as follows: 1,321,479 by by BV III QP, 88,852 by BV III, 39,924 by BV III PF, 111,670 by BV III KG and 26,108 by AM LLC. MPM BioVentures III GP, L.P. ("BVIII GP") and MPM BioVentures III LLC ("BVIII LLC") are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC. The shares were sold as follows: 158,386 by by BV III QP, 10,650 by BV III, 4,785 by BV III PF, 13,384 by BV III KG and 3,129 by AM LLC. The shares are held as follows: 1,163,093 by by BV III QP, 78,202 by BV III, 35,139 by BV III PF, 98,286 by BV III KG and 22,979 by AM LLC. BVIII GP and BVIII LLC are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC. The shares were sold as follows: 236,772 by by BV III QP, 15,919 by BV III, 7,154 by BV III PF, 20,008 by BV III KG and 4,678 by AM LLC. The price in Column 4 is a weighted average sale price. The prices actually ranged from $2.50 to $2.51. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The shares are held as follows: 926,321 by by BV III QP, 62,283 by BV III, 27,985 by BV III PF, 78,278 by BV III KG and 18,301 by AM LLC. BVIII GP and BVIII LLC are the direct and indirect general partners of BV III QP, BV III, BV III PF and BV III KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM LLC. /s/ Luke Evnin 2014-01-09